Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Nucl Med Biol. 2010 May;37(4):479–486. doi: 10.1016/j.nucmedbio.2010.01.006

FIGURE 3.

FIGURE 3

The utility of [18F]FPBM, a SERT ligand, was evaluated in the 6-hydroxydopamine unilateral lesioned rats (rats #1-3) through PET imaging. [18F]FPBM (37-57 MBq), was injected through a catheter placed in the tail vein of the rat while under isoflurane anesthesia. (A) Summed PET images (4 hrs) of a normal control rat showed [18F]FPBM localization to SERT-rich regions such as the thalamus and striatum. (B) In rat #1 there was [18F]FPBM binding in the right striatum but decreased binding in the left striatum (white arrow). (C) In Rat #2 there appeared to be comparable amounts of [18F]FPBM binding between the left (white arrow) and right striatum. (D) There was a clear loss of [18F]FPBM binding in the left striatum (white arrow) of rat #3. Nonspecific binding in the nasal cavity (NC) and Harderian glands (HG) can also be seen in these images.